Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. (Q44257436)

1 December 2017

Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. (English)

1 reference

1 December 2017

1 reference

4

1 reference

1 December 2017

Michael K Chapko

1

1 reference

1 December 2017

Helen S Yee

series ordinal

2

1 reference

1 December 2017

Alexander Monto

series ordinal

3

1 reference

1 December 2017

language of work or name

English

0 references

publication date

29 December 2009

1 reference

1 December 2017

1 reference

1 December 2017

28

1 reference

1 December 2017

7

1 reference

1 December 2017

1726-1731

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Cost-Effectiveness of Hepatitis A/B Vaccine versus Hepatitis B Vaccine in Public Sexually Transmitted Disease Clinics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

An Economic Assessment of Pre-Vaccination Screening for Hepatitis A and B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Cost-effectiveness analysis of hepatitis A vaccination strategies for adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Cost-effectiveness analysis of hepatitis A prevention in travellers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Risks associated with hepatitis A and hepatitis B in patients with hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

What is the price of life and why doesn't it increase at the rate of inflation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.019

10.1016/J.VACCINE.2009.12.019

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference